S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News

+0.12 (+8.73%)
(As of 05/13/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
48,297 shs
Average Volume
47,019 shs
Market Capitalization
$22.62 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RVPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Reviva Pharmaceuticals logo

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.


RVPH: 2021 Results
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.90 per share


Net Income
$-8.52 million
Pretax Margin




Free Float
Market Cap
$22.62 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.28 out of 5 stars

Medical Sector

281st out of 1,403 stocks

Pharmaceutical Preparations Industry

107th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Reviva Pharmaceuticals (NASDAQ:RVPH) Frequently Asked Questions

Is Reviva Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Reviva Pharmaceuticals stock.
View analyst ratings for Reviva Pharmaceuticals
or view top-rated stocks.

When is Reviva Pharmaceuticals' next earnings date?

Reviva Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022.
View our earnings forecast for Reviva Pharmaceuticals

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) issued its quarterly earnings results on Tuesday, March, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.24).
View Reviva Pharmaceuticals' earnings history

What price target have analysts set for RVPH?

2 brokers have issued 12-month price targets for Reviva Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Reviva Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 568.9% from the stock's current price.
View analysts' price targets for Reviva Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reviva Pharmaceuticals' key executives?
Reviva Pharmaceuticals' management team includes the following people:
  • Dr. Laxminarayan Bhat Ph.D., Founder, CEO, Pres & Director (Age 56, Pay $600.05k)
  • Mr. Narayan Prabhu, Chief Financial Officer (Age 50, Pay $275k)
  • Dr. Marc Cantillon, Chief Medical Officer (Age 63, Pay $501.98k)
What is Reviva Pharmaceuticals' stock symbol?

Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.08%), Raymond James & Associates (0.09%) and Renaissance Technologies LLC (0.08%).

Which institutional investors are selling Reviva Pharmaceuticals stock?

RVPH stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..

Which institutional investors are buying Reviva Pharmaceuticals stock?

RVPH stock was purchased by a variety of institutional investors in the last quarter, including Raymond James & Associates, and Renaissance Technologies LLC.

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reviva Pharmaceuticals' stock price today?

One share of RVPH stock can currently be purchased for approximately $1.50.

How much money does Reviva Pharmaceuticals make?

Reviva Pharmaceuticals has a market capitalization of $22.62 million. The company earns $-8.52 million in net income (profit) each year or ($0.560010) on an earnings per share basis.

How many employees does Reviva Pharmaceuticals have?

Reviva Pharmaceuticals employs 5 workers across the globe.

What is Reviva Pharmaceuticals' official website?

The official website for Reviva Pharmaceuticals is www.revivapharma.com.

How can I contact Reviva Pharmaceuticals?

Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com.

This page was last updated on 5/15/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.